Antagonists of the αvβ3 and αvβ5 integrins inhibit angiogenesis in cancer, arthritis and ischemic retinopathy. However, a surprising new report suggests that knockout mice lacking β3 and/or β5 integrins show enhanced, rather than reduced angiogenesis. (pages 27–34)